Bronchiectasis Clinical Trials

Find Bronchiectasis Clinical Trials Near You

AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis

Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB). The trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care. Participants will be randomized in a 1:1 allocation ratio to standard care plus matching placebo or standard care plus azithromycin. The primary analysis will follow the intention-to-treat (ITT) principle. The AMBER trial is embedded within the Assiut University bronchiectasis translational research platform and is linked to the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework and the Bronchiectasis Phenotype Identification Model (BPIM). BASE and BPIM are not used for randomization stratification and will not modify the primary randomized comparison. The locked Version 1.0 methodological disclosure document, protocol, and statistical analysis plan (SAP), primary sample-size source code, and endpoint-level sample-size support matrix are archived in Zenodo: https://doi.org/10.5281/zenodo.20178963. The AMBER public preregistration is also available through the Open Science Framework (OSF) under Digital Object Identifier (DOI) 10.17605/OSF.IO/RE54V.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients aged 18 years or older.

• Clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

• Diagnosis supported by clinical assessment and high-resolution computed tomography (HRCT).

• Patients attending outpatient clinics, inpatient wards, respiratory follow-up services, or routine bronchiectasis care pathways at Assiut University Hospitals during the enrollment period.

• Suitable for baseline disease-signature assessment.

• Able to undergo protocol-defined clinical, functional, radiological, oxygenation, inflammatory, symptom, and safety assessment.

• Able to complete planned 12-month follow-up.

• Eligible for randomization after baseline safety evaluation.

• Written informed consent obtained from the participant or legal representative.

Locations
Other Locations
Egypt
Assiut university-Faculty of Medicine
RECRUITING
Asyut
Contact Information
Primary
Ahmad M Shaddad, MD
shaddad_ahmad@aun.edu.eg
+201111171930
Time Frame
Start Date: 2026-06-29
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 500
Treatments
Placebo_comparator: Placebo Control Arm
Participants assigned to this arm will receive standard bronchiectasis care plus matching placebo once daily for 12 months. Standard care may include mucolytics, bronchodilators, chest physiotherapy, patient education, airway-clearance support, and treatment of acute exacerbations with antibiotics with or without systemic corticosteroids according to clinical indication. The matching placebo will not contain active azithromycin.
Experimental: Experimental Azithromycin Arm
Participants assigned to this arm will receive standard bronchiectasis care plus azithromycin 250 milligrams orally once daily for 12 months. Standard care may include mucolytics, bronchodilators, chest physiotherapy, patient education, airway-clearance support, and treatment of acute exacerbations with antibiotics with or without systemic corticosteroids according to clinical indication.
Related Therapeutic Areas
Sponsors
Leads: Assiut University

This content was sourced from clinicaltrials.gov